TIANFU-CHEM - Imatinib CAS NO.152459-95-5

FOB Price: USD: 1,000.00-1,000.00 /Kilogram Get Latest Price
Min.Order: 1 Gram
Payment Terms: L/C,D/A,D/P,T/T,MoneyGram,Other
Available Specifications:
1(1-100)Kilogram1000/Kilogram1USD

Product Details

Keywords

Imatinib
152459-95-5
C29H31N7O

Quick Details

ProName: TIANFU-CHEM - Imatinib
CasNo: 152459-95-5
Molecular Formula: C29H31N7O
Appearance: Solid
Application: Organic synthesis
DeliveryTime: PROMPT
PackAge: IN 25kg drums
Port: SHANGHAI
ProductionCapacity: 10 Metric Ton/Month
Purity: 99.0%
Storage: In Room Temperature
Transportation: As per MSDS
LimitNum: 1 Gram
Heavy metal: N/A
Grade: Industrial Grade,Food Grade,Pharma Gra...

Superiority

Henan Tianfu Chemical Co., Ltd. is located in Zhengzhou High-tech Development Zone with import and export license.

We passed ISO 9001:2008 in 2009, and won "High-tech Enterprise" by provincial government in 2013.The objective of the company is to put quality first and put our customer’s needs first - the satisfaction of our customers is the company's ultimate goal.

Improving product quality and service level is our responsibility, and creating more value for our customer’s is our purpose. We are constantly striving to make Henan Tianfu a leading chemical supplier, and hope to create a better future with you.

Details

Imatinib Basic information

Product description Approved indications in Europe, the United States and other countries Precautions Uses

Product Name: Imatinib

Synonyms: 4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE;Imatinib (4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide;Imatinib free base;Veenat;IMatinib(STI571);Imantinib base;4-(4-Methyl-piperazin-1-ylMethyl)-N-[4-Methyl-3-(4-pyridin-3-yl-pyriMidin-2-ylaM;IMatinib-D4

CAS: 152459-95-5

MF: C29H31N7O

MW: 493.6

EINECS:

Product Categories: Pharmaceutical intermediate;Imatinib;Aromatics;Heterocycles;Impurities;Intermediates & Fine Chemicals;Pharmaceuticals;API;GLEVEEC;Antineoplastic;Anti-cancer & immunity;Inhibitors;Molecular Targeted Antineoplastic

Mol File: 152459-95-5.mol

Imatinib Structure

Imatinib Chemical Properties

Melting point 208-210°C (dec.)

storage temp. Refrigerator

pka pKa1 8.07; pKa2 3.73; pKa3 2.56; pKa4 1.52(at 25℃)

Merck 14,4902

CAS DataBase Reference 152459-95-5(CAS DataBase Reference)

Safety Information

Safety Statements 24/25

RTECS CV5585673

MSDS Information

Imatinib Usage And Synthesis

Product description Imatinib is a kind of oral drugs used for the treatment of the chronic myelogenous leukemia (abbreviated CML) of positive symptoms of Philadelphia chromosome (Ber-Abl). It is suitable for being applied to adult patients in acute transformation phase, accelerated phase, and chronic phase with treatment failure with interferon. CML is a kind of hematopoietic stem cell disease caused by the DNA abnormalities in the bone marrow stem cells. DNA abnormalities will produce abnormal proteins and interfere with the normal generation process of the white blood cells in the bone marrow, resulting in the sharp increase in the number of white blood cells. CML is divided into three phases including chronic phase, accelerated phase and crisis phase with the average survival period of the patients in crisis phase being only 2-3 months.

Imatinib is also effective in treating the gastrointestinal stromal tumor with the efficiency being about 50%.

Approved indications in Europe, the United States and other countries Novartis's imatinib (imatinib, Glivec) had been approved in Switzerland for being used as first-line drug for the treatment of early-stage adult chronic myelogenous leukemia and can also be applied to patients with various types of chronic granulocytic leukemia. Switzerland is the first countries which had approved to additionally include the above two indications of this drug.

On July 28, 2006, the European Agency for the Evaluation of Medicinal Products (EMEA) had recommended the imatinib (Gleevec) of the Novartis Company for the treatment of two new indications-dermatofibrosarcoma protuberans (DFSP) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL). These final approvals of these two indications still need to wait the decision of the European Food and Drug Administration.

In addition, Novartis has announced that the application of imatinib in treating hypereosinophilic syndrome and systemic mastocytosis is still in the approval process of FDA and EMEA.

The drug has currently been approved in Europe, the United States and other countries for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph + CML) and gastrointestinal stromal tumors.

The above information is edited by the Chemicalbook of Dai Xiongfeng.

Precautions When combined with Ketoconazole, itraconazole, erythromycin, clarithromycin, the Cmax of this drug can (the maximum plasma concentration after the first drug administration) be increased by an average of 26% with the AUC being increased by 40%.

The inducers of the metabolizing enzyme of hepatic drugs such as dexamethasone, phenytoin, carbamazepine, rifampicin and barbiturates can significantly reduce blood concentration of the drug.

When the CYP3A4 metabolized substrates such as simvastatin, cyclosporine, pimozide, etc. were used in combined with imatinib, the plasma concentration of those drugs can be increased due to its competing with the drug enzyme.

Uses Imatinib can be used for the treatment of the chronic myelogenous leukemia (abbreviated CML) of positive symptoms of Philadelphia chromosome (Ber-Abl). It is suitable for being applied to adult patients in acute transformation phase, accelerated phase, and chronic phase with treatment failure with interferon.

Chemical Properties Orange Solid

Uses Imatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively. Imatinib also known as Gleevec, Glivec, CGP-57148B, STI-571 & Imatinib

Uses antineoplastic

Uses atypical antipsychotic

Uses Imatinib impurity.

Imatinib Preparation Products And Raw materials